Q3 2017 EPS Estimates for Amarin Corporation PLC Lifted by Analyst (AMRN)

Amarin Corporation PLC (NASDAQ:AMRN) – Equities research analysts at Jefferies Group increased their Q3 2017 EPS estimates for shares of Amarin Corporation PLC in a research report issued to clients and investors on Monday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.06). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Amarin Corporation PLC’s FY2017 earnings at ($0.22) EPS.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. During the same period in the previous year, the business earned ($0.07) earnings per share. The business’s quarterly revenue was up 37.0% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Q3 2017 EPS Estimates for Amarin Corporation PLC Lifted by Analyst (AMRN)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/13/q3-2017-eps-estimates-for-amarin-corporation-plc-lifted-by-analyst-amrn.html.

A number of other equities analysts also recently weighed in on the company. Zacks Investment Research upgraded Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Tuesday, October 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. ValuEngine upgraded Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 31st. BidaskClub downgraded Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $7.20.

Shares of Amarin Corporation PLC (AMRN) opened at 3.35 on Wednesday. Amarin Corporation PLC has a 52-week low of $2.75 and a 52-week high of $4.47. The firm’s market capitalization is $907.15 million. The stock has a 50 day moving average price of $3.32 and a 200-day moving average price of $3.33.

In related news, insider Steven B. Ketchum sold 63,479 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.72% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Westside Investment Management Inc. lifted its stake in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 1,500 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Amarin Corporation PLC by 1.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 2,050 shares during the last quarter. State Street Corp lifted its stake in Amarin Corporation PLC by 1.3% in the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 2,640 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 3,413 shares during the last quarter. Institutional investors and hedge funds own 37.76% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride lev

Amarin Corporation PLC (NASDAQ:AMRN) – Equities research analysts at Jefferies Group increased their Q3 2017 EPS estimates for shares of Amarin Corporation PLC in a research report issued to clients and investors on Monday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.06). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Amarin Corporation PLC’s FY2017 earnings at ($0.22) EPS.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. During the same period in the previous year, the business earned ($0.07) earnings per share. The business’s quarterly revenue was up 37.0% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Q3 2017 EPS Estimates for Amarin Corporation PLC Lifted by Analyst (AMRN)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/10/13/q3-2017-eps-estimates-for-amarin-corporation-plc-lifted-by-analyst-amrn.html.

A number of other equities analysts also recently weighed in on the company. Zacks Investment Research upgraded Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Tuesday, October 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. ValuEngine upgraded Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 31st. BidaskClub downgraded Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $7.20.

Shares of Amarin Corporation PLC (AMRN) opened at 3.35 on Wednesday. Amarin Corporation PLC has a 52-week low of $2.75 and a 52-week high of $4.47. The firm’s market capitalization is $907.15 million. The stock has a 50 day moving average price of $3.32 and a 200-day moving average price of $3.33.

In related news, insider Steven B. Ketchum sold 63,479 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.72% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Westside Investment Management Inc. lifted its stake in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 1,500 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Amarin Corporation PLC by 1.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 2,050 shares during the last quarter. State Street Corp lifted its stake in Amarin Corporation PLC by 1.3% in the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 2,640 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after purchasing an additional 3,413 shares during the last quarter. Institutional investors and hedge funds own 37.76% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Earnings History and Estimates for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply